ArticleFrontiers in immunology2025
SPP1 as a biomarker for idiopathic membranous nephropathy progression and its regulatory role in inflammation and fibrosis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A cross-model single-cell atlas reveals conserved involvement of osteopontin in polycystic kidney disease.JCI insight · 2026Article
- WTAP Deficiency Promotes Podocyte PANoptosis and FSGS via SPP1 Signaling.Circulation research · 2026Article
- Integrated Transcriptomic and Machine Learning Analyses Identify KCNN3 and TLR10 as Candidate Cell-Type-Associated Molecules in Idiopathic Membranous Nephropathy.International journal of general medicine · 2026Article
- Spatial transcriptomic analysis of kidney biopsies identifies activation of complement and SPP1 networks inFrontiers in nephrology · 2026Article
- The effects of traditional Chinese botanical medicine on membranous nephropathy.Frontiers in pharmacology · 2026Review
- Single-cell analysis reveals shared adaptive responses across different types of podocyte injury.Frontiers in immunology · 2025Article
- A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in middle-aged and elderly populations. Early intervention can delay disease progression and improve patient outcomes. This study aims to identify urinary biomarkers for IMN and investigate their association with disease progression, offering new insights for precise diagnosis and treatment. Methods: This study began with RNA sequencing of three urine sample types (first-void morning urine, second-void morning urine, and random urine), combined with single-cell RNA sequencing of renal tissues. Bioinformatics analyses-including differential gene expression screening, machine learning, and molecular function annotation-were employed to identify potential IMN biomarkers. Furthermore, we established both a siRNA-mediated gene silencing model and a lentivirus transfection-mediated gene overexpression model in HK-2 cells. Subsequently, we investigated the functional mechanisms of the candidate biomarkers through qRT-PCR, Western blot, immunohistochemistry, and immunofluorescence assays. Results: SPP1 was identified as a promising biomarker for IMN, demonstrating a critical role in promoting fibrosis and inflammatory responses associated with the disease. These findings suggest its potential as a novel therapeutic target for IMN intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.